In-vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates
values of 0.38 μg/ml and 0.5 μg/ml, respectively, and 98.3% susceptibility. These findings support levonadifloxacin as a promising therapeutic option for MRSA infections.
Authors
- Neelam Taneja
- Imola Jamir
- Vishal Kumar Singh
- Shubhangi Kansal
- Sukriti Yadave
- Archana Angrup
Institutions
- All India Institute of Medical Sciences Rishikesh (IN)
- Post Graduate Institute of Medical Education and Research (IN)
- Nagaland University (IN)
Publication Details
- Journal
- Indian Journal of Medical Microbiology
- Published
- 2026-04-06
- DOI
- https://doi.org/10.1016/j.ijmmb.2026.101112
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wockhardt